ImmuneBiotech in the news

Press Releases

2016-05-04ImmuneBiotech AB has been awarded a grant by Innovationskontor Syd’s ACCELERATOR program

ImmuneBiotech AB has been awarded a grant by Innovationskontor Syd to support the development of a probiotic based therapy for one of the most prevalent, wide spread diseases, Irritable Bowel Syndrome (IBS).

Conferences

1
Shahram Lavasani is an invited speaker at Pharmaceutical Microbiology in London, UK.
January 22–23, 2018

2
Shahram Lavasani is an invited speaker at GUT-BRAIN AXIS Summit in San Francisco, USA.
December 12–14, 2017 The brochure

3
Shahram Lavasani is an invited speaker at Microbiome Human Nutrition Summit in Boston, USA.
November 14–16, 2017

4
Shahram Lavasani is an invited speaker at Pharmaceutical Microbiology East Coast 2017 in Iselin, New Jersey, USA.
November 13-14, 2017

5
Shahram Lavasani is an invited speaker at Medicon Valley Alliance, Microbiome Summit, Copenhagen, Sweden.
October 4-5, 2017

6
ImmuneBiotech is attending to the Nordic Life Science (NLS) Days in Malmö, Sweden.
September 12-14, 2017

immune-thumb
Shahram Lavasani is an invited speaker at Microbiome Discovery & Development Congress in Berlin, Germany
June 12-13, 2017

microbiom2
Shahram Lavasani is an invited speaker at Probiotics Congress and 4th Microbiome R&D and Business Collaboration Forum: Europe in Amsterdam, The Netherlands
April 3-4, 2017

microbiom
European Microbiome Congress, London, UK
ImmuneBiotech has been selected to PITCH YOUR MICROBES at the Congress
November 30-December 1, 2016

jj
JLINX Symposium, Janssen Pharmaceutica, Beerse, Belgium
October 19, 2016

Nordic Life Science Days in Stockholm
September 14-15, 2016

Southern Sweden Going Global project
2016

BioEurope Spring 2016
April 3-6, 2016
Stockholm, Sweden

Scientific Publications

Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells.
Nouri M, Bredberg A, Weström B, Lavasani S.
PLoS One. 2014 Sep 3;9(9)

Targeting versus tinkering: explaining why the clinic is frustrated with molecular mapping of disease mechanisms.
Bredberg A, Lavasani S.
Med Hypotheses. 2013 Oct;81(4):553-6

A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.
Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B.
PLoS One. 2010 Feb 2;5(2)

ImmuneBiotech in the News